Clinical Trial

Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas

Study acronym: SLURP
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 13, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
Previous studies have confirmed the great potential of quantitative fluorescence molecular endoscopy (qFME) when looking at additional lesion detection initially missed by high-definition white light endoscopy (HD-WLE) for surveillance of Barrett's esophagus.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-02-24.
Status change: Not Yet Recruiting → Recruiting 2026-04-07
Trial Details
NCT Number NCT05745857
Lead Sponsor University Medical Center Groningen
Conditions Barrett's Esophagus Without Dysplasia, Barrett Oesophagitis With Dysplasia, Esophageal Adenocarcinoma
Enrollment 25 participants
Start Date 2023-09-15
Primary Completion 2026-05 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-13